Paraneoplastic Syndromes: Clinical Trials

455 trials for Paraneoplastic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

174 completed, 106 recruiting, 56 unknown, 33 active not recruiting. 98 Phase 3, 89 Phase 2, 64 Not applicable, 44 Phase 1, 14 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 398Completed 46, Recruiting 21, Active not recruiting 12, Terminated 8, Unknown 7, Enrolling by invitation 2, Not yet recruiting 1, Withdrawn 1
Phase 289Completed 34, Recruiting 24, Terminated 12, Active not recruiting 9, Not yet recruiting 3, Unknown 3, Withdrawn 3, Enrolling by invitation 1
Not applicable64Completed 26, Unknown 12, Recruiting 11, Active not recruiting 6, Not yet recruiting 5, Terminated 2, Enrolling by invitation 1, Withdrawn 1
Phase 144Recruiting 14, Completed 12, Not yet recruiting 7, Active not recruiting 4, Withdrawn 3, Terminated 2, Unknown 2
Early Phase 114Not yet recruiting 5, Recruiting 4, Completed 2, Terminated 1, Unknown 1, Withdrawn 1
Phase 414Completed 6, Recruiting 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1

Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Myasthenia Gravis Generalized
Not yet recruitingBioSensics252027-03-152026-10-13
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
HN2301 injection - Generalized Myasthenia Gravis
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd62026-12-312026-08-12
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
GT802 Injection - Generalized Myasthenia Gravis (gMG)
Early Phase 1Not yet recruitingDaishi Tian122026-12-012026-11-05
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Ublituximab, Placebo - Myasthenia Gravis
Phase 2RecruitingTG Therapeutics, Inc.1202026-11-012026-10-29
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
MyoSense 360 - Myasthenia Gravis, Generalized
Not applicableRecruitingAd scientiam1002026-10-062026-11-05
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
Not yet recruitingThird Affiliated Hospital, Sun Yat-Sen University3002026-10-012026-10-05
Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis
Myasthenia Gravis, Thymoma
Not yet recruitingAssiut University302026-10-012026-10-01
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Phase 2RecruitingMayo Clinic902026-10-012026-09-25
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab - Ocular Myasthenia Gravis
Phase 3RecruitingUCB Biopharma SRL1002026-09-162026-11-06
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma
Not yet recruitingIRCCS San Raffaele402026-09-152026-05-06
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
EA5 - Generalized Myasthenia Gravis (gMG)
Phase 1Not yet recruitingShanghai Lanyi Therapeutics Co., Ltd.182026-09-152026-09-14
Pattern of AFP in Chhidren Admitted at Sohag University Hospital
Observitional follow-up - Acute Flaccid Paralysis, AFP
Not yet recruitingMohamed Aboelhamd Ali302026-09-012026-09-11
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
SHR-2173 injection, Placebo - Generalized Myasthenia Gravis
Phase 2RecruitingGuangdong Hengrui Pharmaceutical Co., Ltd602026-08-282026-10-22
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat, Placebo - Hypertension, Hypercortisolemia
Phase 4RecruitingRECORDATI GROUP632026-08-262026-11-02
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Myasthenia Gravis (MG)
RecruitingGeorge Washington University182026-08-192026-10-05
Sexual and Urinary Dysfunctions in Generalized Myasthenia
No intervetion - Myasthenia Gravis (MG)
Not yet recruitingCentre Hospitalier Universitaire de Nice1502026-07-302026-07-01
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Ravulizumab - Generalized Myasthenia Gravis, gMG
Phase 3RecruitingAlexion Pharmaceuticals, Inc.202026-07-272026-10-21
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Inebilizumab - Generalized Myasthenia Gravis
Phase 2RecruitingAmgen152026-07-212026-10-23
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG)
Phase 2Recruitingargenx402026-07-102026-11-04
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Cushing s Syndrome, Cushing Disease
RecruitingAzienda Ospedaliero-Universitaria di Modena20002026-07-092026-11-09

Showing 20 of 455. Sign in to see all of them.

Narrower conditions

Myasthenia Gravis (320)  ·  ACTH Syndrome, Ectopic (44)  ·  Multiple Sclerosis (35)  ·  Myelitis, Transverse (32)  ·  Neuromyelitis Optica (32)  ·  Autoimmune Diseases of the Nervous System (29)  ·  Cushing Syndrome (22)  ·  Lambert-Eaton Myasthenic Syndrome (22)  ·  Autoimmune Diseases (21)  ·  Zollinger-Ellison Syndrome (16)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (15)  ·  Anti-N-Methyl-D-Aspartate Receptor Encephalitis (13)  ·  Hypertension (13)  ·  Guillain-Barre Syndrome (12)  ·  Neuromuscular Diseases (11)

Broader conditions

Neoplasms (452)  ·  Neoplasms by Site (415)  ·  Nervous System Diseases (398)  ·  Nervous System Neoplasms (390)  ·  Neurodegenerative Diseases (389)  ·  Paraneoplastic Syndromes, Nervous System (388)  ·  Immune System Diseases (382)  ·  Autoimmune Diseases (364)  ·  Autoimmune Diseases of the Nervous System (354)  ·  Neuromuscular Junction Diseases (330)  ·  Neuromuscular Diseases (328)  ·  Central Nervous System Diseases (88)  ·  Pathological Conditions, Signs and Symptoms (87)  ·  Demyelinating Diseases (66)

Interventions

Amifampridine (13)  ·  Rituximab (12)  ·  efgartigimod alfa (11)  ·  rozanolixizumab (11)  ·  Cyclophosphamide (9)  ·  Prednisone (8)  ·  eculizumab (8)  ·  ravulizumab (8)  ·  zilucoplan (8)  ·  Immunoglobulins, Intravenous (7)  ·  Pyridostigmine Bromide (7)  ·  Tacrolimus (7)  ·  Mycophenolic Acid (6)  ·  fludarabine (6)  ·  telitacicept (6)

Sponsors

Alexion Pharmaceuticals, Inc. (20)  ·  argenx (17)  ·  UCB Biopharma SRL (14)  ·  Corcept Therapeutics (9)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  AstraZeneca (6)  ·  Charite University, Berlin, Germany (6)  ·  Hospices Civils de Lyon (6)  ·  Mayo Clinic (6)  ·  Novartis Pharmaceuticals (6)  ·  Catalyst Pharmaceuticals, Inc. (5)  ·  Centre Hospitalier Universitaire de Nice (5)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (5)  ·  Huashan Hospital (5)

Countries

United States (215)  ·  China (94)  ·  Italy (81)  ·  France (71)  ·  Germany (69)  ·  Canada (66)  ·  Spain (62)  ·  Poland (60)  ·  Japan (49)  ·  United Kingdom (49)  ·  Belgium (33)  ·  Netherlands (32)  ·  Denmark (30)  ·  Serbia (23)  ·  South Korea (23)

Top investigators

Andreas Meisel, Prof. Dr. med. (3)  ·  Benjamin Greenberg, MD (3)  ·  Daishi Tian (3)  ·  Irina Bancos, MD (3)  ·  Raffaele Iorio (3)  ·  Andreas G Moraitis, MD (2)  ·  Andreas Moraitis, MD (2)  ·  Antonio Guglietta, MD (2)  ·  Chongbo Zhao (2)

Results publications

PMID 37059507, PMID 42388397, PMID 21211990, PMID 25013998, PMID 26507877, PMID 30905021, PMID 32189108, PMID 32426038, PMID 32700461, PMID 33219142, PMID 33229455, PMID 33329303, PMID 33676197, PMID 34146511, PMID 34498507, PMID 34590717, PMID 35058882, PMID 35350948, PMID 37059508, PMID 37318239, PMID 38099334, PMID 38400914, PMID 39068745, PMID 39314260, PMID 40105996, PMID 40504283, PMID 42855714, PMID 10227640, PMID 10625901, PMID 10658825, PMID 10891897, PMID 11339776, PMID 11383846, PMID 11459743, PMID 12236201, PMID 12691631, PMID 15645403, PMID 15958281, PMID 16263996, PMID 16267188, PMID 16831964, PMID 16849828, PMID 16900450, PMID 17264722, PMID 17767471, PMID 18173374, PMID 18256991, PMID 18323730, PMID 18507843, PMID 18567886

NIH funding

2023 (13), 2025 (11), 2018 (6), 2019 (6), 2016 (4), P30CA016672 (2), U54NS115054 (2), 1RC3NS070670-01 (1), 2008 (1), 2014 (1), 2015 (1), 2017 (1), K23DK142038 (1), N01CM62202 (1), R01EY029437 (1)